Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
Actinium Pharmaceuticals is presenting first-in-human Phase 1 data for ATNM-400 in metastatic castration-resistant prostate cancer today at EANM 2026 in Vienna. A companion preclinical presentation covers KRAS- and ALK-driven non-small cell lung cancer models, supporting a mutation-agnostic, pan-tumor development rationale for the HER3-targeted Actinium-225 radioconjugate.
Key figures
- Drug Name
- ATNM-400
- Phase Of Trial
- Phase 1
- Patents
- ~250 patents and patent applications
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.